A Retrospective Study of the Efficacy of Sulbactam in the Treatment of Patients with Extensively Drug-Resistant Acinetobacter Baumannii Infections
Research Square (Research Square)(2024)
摘要
Sulbactam (SBT) is one of the most significant treatments for patients with extensively drug-resistant Acinetobacter baumannii (XDR-AB). However, the efficacy and safety of SBT and its high dose regimen has not been well documented. This retrospective study aimed to assess the efficacy and safety of SBT-based treatment, particularly at high-dose (≥ 6 g/day), for XDR-AB infection. A total of 52 XDR-AB infected patients treated with intravenous SBT at Peking Union Medical College Hospital were included. The primary outcome was 28-day all-cause mortality, while the secondary outcome was 14-day clinical response and the time of response. The formulation of SBT in our study is 0.5 g per vial. Among the patients, the 28-day all-cause mortality rate was 36.5
更多查看译文
关键词
Sulbactam,Single formulation,Carbapenem-resistant,High dose
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要